Outlook Therapeutics Taps New CFO to Lead LYTENAVA U.S. Launch
Event summary
- Outlook Therapeutics appoints Kevin Lundquist as CFO effective September 1, 2026, to lead U.S. commercial launch of LYTENAVA following FDA approval.
- Lundquist brings over 20 years of finance experience in pharmaceuticals, biotech, and medical technology, including IPO and commercial-stage leadership.
- Former CFO Lawrence Kenyon steps down but will support transition through September 30, 2026.
- Lundquist receives inducement grant of 500,000 stock options, vesting over four years.
- LYTENAVA is the only FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration (AMD).
The big picture
Outlook Therapeutics' appointment of Kevin Lundquist as CFO underscores the strategic shift from clinical development to commercial execution following LYTENAVA's FDA approval. The move reflects the company's focus on scaling its financial and operational capabilities to capitalize on the U.S. market opportunity. Lundquist's experience in leading finance functions for commercial-stage biopharmaceutical companies positions Outlook Therapeutics to navigate the complexities of launching and marketing a novel ophthalmic therapy.
What we're watching
- Execution Risk
- Whether Lundquist can rapidly build scalable financial and operational infrastructure for LYTENAVA's U.S. launch.
- Market Adoption
- The pace at which LYTENAVA gains market share in the competitive retinal disease treatment space.
- Financial Discipline
- How Lundquist allocates capital to balance growth and profitability as Outlook Therapeutics transitions to a commercial-stage company.